CN116194479A - 抗tau抗体 - Google Patents

抗tau抗体 Download PDF

Info

Publication number
CN116194479A
CN116194479A CN202180062368.9A CN202180062368A CN116194479A CN 116194479 A CN116194479 A CN 116194479A CN 202180062368 A CN202180062368 A CN 202180062368A CN 116194479 A CN116194479 A CN 116194479A
Authority
CN
China
Prior art keywords
seq
set forth
specific binding
sequence set
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180062368.9A
Other languages
English (en)
Chinese (zh)
Inventor
查尔斯·R·哈林顿
S·帕利里·索曼
A·J·R·波特
克劳德·M·维希克
M·阿拉斯托
L·K·潘妮
R·洛夫特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gt Innovation Co
Original Assignee
Gt Innovation Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gt Innovation Co filed Critical Gt Innovation Co
Publication of CN116194479A publication Critical patent/CN116194479A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180062368.9A 2020-07-10 2021-07-09 抗tau抗体 Pending CN116194479A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2010652.2A GB202010652D0 (en) 2020-07-10 2020-07-10 Anti-tau antibodies
GB2010652.2 2020-07-10
PCT/EP2021/069160 WO2022008719A1 (en) 2020-07-10 2021-07-09 Anti-tau antibodies

Publications (1)

Publication Number Publication Date
CN116194479A true CN116194479A (zh) 2023-05-30

Family

ID=72140057

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062368.9A Pending CN116194479A (zh) 2020-07-10 2021-07-09 抗tau抗体

Country Status (10)

Country Link
US (1) US20230257452A1 (https=)
EP (1) EP4178980A1 (https=)
JP (1) JP7796719B2 (https=)
KR (1) KR20230038721A (https=)
CN (1) CN116194479A (https=)
AU (1) AU2021306653A1 (https=)
CA (1) CA3185175A1 (https=)
GB (1) GB202010652D0 (https=)
TW (1) TWI912331B (https=)
WO (1) WO2022008719A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample
KR20240134175A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 샘플에서 타우(tau) 단백질 단편을 검출하기 위한 방법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
WO2018031361A2 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
CN110290801A (zh) * 2016-12-07 2019-09-27 基因泰克公司 抗tau抗体和使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0106953D0 (en) 2001-03-20 2001-05-09 Univ Aberdeen Neufofibrillary labels
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
WO2007110630A1 (en) 2006-03-29 2007-10-04 Wista Laboratories Ltd. Thioninium compounds and their use
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
CA2896066C (en) * 2012-12-21 2022-07-12 Biogen Ma Inc. Human anti-tau antibodies
BR112016010454A2 (pt) * 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
EP3601337A1 (en) * 2017-03-28 2020-02-05 Genentech, Inc. Methods of treating neurodegenerative diseases
US20250147051A1 (en) * 2022-01-12 2025-05-08 Gtinvent Limited Method for detecting a tau protein in a saliva sample

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140303041A1 (en) * 2004-04-15 2014-10-09 University Of Florida Research Foundation Inc. In vitro diagnostic devices for nervous system injury and other neural disorders
WO2015004163A1 (en) * 2013-07-08 2015-01-15 Adx Neurosciences Anti-tau monoclonal antibodies
WO2018031361A2 (en) * 2016-08-09 2018-02-15 Eli Lilly And Company Combination therapy
CN110290801A (zh) * 2016-12-07 2019-09-27 基因泰克公司 抗tau抗体和使用方法

Also Published As

Publication number Publication date
AU2021306653A1 (en) 2023-03-02
US20230257452A1 (en) 2023-08-17
TW202214686A (zh) 2022-04-16
JP2023533768A (ja) 2023-08-04
EP4178980A1 (en) 2023-05-17
GB202010652D0 (en) 2020-08-26
KR20230038721A (ko) 2023-03-21
JP7796719B2 (ja) 2026-01-09
TWI912331B (zh) 2026-01-21
CA3185175A1 (en) 2022-01-13
WO2022008719A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
EP3160998B1 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
JP2021515556A (ja) 抗ｐｈｆ−タウ抗体及びその使用
CN116194479A (zh) 抗tau抗体
TWI892069B (zh) 用於偵測Tau蛋白或其片段的方法與套組
US11472869B2 (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
RU2855123C1 (ru) Антитела против тау
US20250355001A1 (en) Method for detecting a tau protein fragment in a sample
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
HK1166331A1 (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases
HK1166331B (en) Use of an anti-tau ps422 antibody for the treatment of brain diseases

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination